{
    "clinical_study": {
        "@rank": "3162", 
        "arm_group": {
            "arm_group_label": "nab-paclitaxel+Cisplatin+gemcitabine", 
            "arm_group_type": "Experimental", 
            "description": "This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the efficacy of nab-paclitaxel plus\n      cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma\n      (PDA)."
        }, 
        "brief_title": "Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms", 
                "Carcinoma, Ductal, Breast"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 1b/2 open-label pilot study evaluating the preliminary efficacy and safety\n      of nab-paclitaxel, cisplatin, and gemcitabine in patients with metastatic pancreatic ductal\n      adenocarcinoma.\n\n      An individual cycle of therapy will be defined as Days 1 and 8 every 21 days.  Multiple\n      cycles may be administered until the patient is withdrawn from therapy.\n\n      Overall response rates as well as individual categories of response (complete response-CR,\n      partial response-PR, stable disease-SD and progressive disease-PD) will be determined using\n      RECIST 1.1.  Time-to-event endpoints, including progression free survival (PFS) and OS\n      (overall survival) will be assessed using the Kaplan-Meier method.  Evaluation of stable\n      disease at 9 weeks will also be assessed.  Toxicity (adverse events) will be recorded using\n      the NCI CTCAE (v4.0, May 2009)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years of age; male or female.\n\n          -  Histologically or cytologically confirmed metastatic pancreatic ductal\n             adenocarcinoma.\n\n          -  Capable of providing informed consent and complying with trial procedures.\n\n          -  Karnofsky Performance Status (KPS) of >/=70%.\n\n          -  Life expectancy >/=12 weeks.\n\n          -  Measurable tumor lesions according to RECIST 1.1 criteria.\n\n          -  Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,\n             surgically sterile, or practicing adequate birth control methods) for the duration of\n             the study.  Women of child bearing potential must have a negative serum or urine\n             pregnancy test at the Screening Visit and be non-lactating.  Both male and female\n             patients of reproductive potential must agree to use a reliable method of birth\n             control during the study.\n\n        Exclusion Criteria:\n\n          -  Patients must have received no previous radiotherapy, surgery, chemotherapy or\n             investigational therapy for the treatment of metastatic disease.  Prior treatments in\n             the adjuvant setting with gemcitabine and/or 5-FU or gemcitabine administered as a\n             radiation sensitizer are allowed, provided at least 6 months have elapsed since\n             completion of the last dose and no lingering toxicities are present.\n\n          -  Palliative surgery and/or radiation treatment less than 4 weeks prior to initiation\n             of study treatment.\n\n          -  Exposure to any investigational agent within 4 weeks prior to initiation of study\n             treatment.\n\n          -  Evidence of central nervous system (CNS) metastasis (negative imaging study, if\n             clinically indicated, within 4 weeks of Screening Visit).\n\n          -  History of other malignancies (except cured basal cell carcinoma, superficial bladder\n             cancer or carcinoma in situ of the cervix) unless documented free of cancer for >/= 5\n             years.\n\n          -  Laboratory values:  Screening serum creatinine > upper limits of normal (ULN); total\n             bilirubin > ULN: alanine aminotransferase (ALT) and AST >/= 2.5 ULN or >/= 5.0 x ULN\n             if liver metastases are present; absolute neutrophil count < 1,500/mm3, platelet\n             concentration < 100,00/mm3, hematocrit level < 27% for females or < 30% for males, or\n             coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT],\n             International Normalized Ratio [INR]) > 1.5 x ULN unless on therapeutic doses of\n             warfarin.\n\n          -  current, serious, clinically significant cardiac arrhythmias as determined by the\n             Investigator.\n\n          -  History of HIV infection.\n\n          -  Active, clinically significant serious infection requiring treatment with\n             antibiotics, anti-virals or anti-fungals.\n\n          -  Major surgery within 4 weeks prior to initiation of study treatment. Any condition\n             that might interfere with the patient's participation in the study or in the\n             evaluation of the study results.\n\n          -  Any condition that is unstable and could jeopardize the patient's participation in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893801", 
            "org_study_id": "PCRT 12-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "nab-paclitaxel+Cisplatin+gemcitabine", 
                "description": "25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle", 
                "intervention_name": "nab-paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Abraxane"
            }, 
            {
                "arm_group_label": "nab-paclitaxel+Cisplatin+gemcitabine", 
                "description": "25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "cisplatinum", 
                    "cis-diamminedichloroplatinum", 
                    "CDDP"
                ]
            }, 
            {
                "arm_group_label": "nab-paclitaxel+Cisplatin+gemcitabine", 
                "description": "1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pancreatic cancer", 
            "pancreatic adenocarcinoma", 
            "Stage IV pancreatic cancer", 
            "pancreas", 
            "pancreatic"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "link": [
            {
                "description": "Additional information about the Pancreatic Cancer Research Team (PCRT)", 
                "url": "http://www.pcrt.org"
            }, 
            {
                "description": "Non-profit Organization", 
                "url": "http://www.tgen.org"
            }, 
            {
                "description": "Related link", 
                "url": "http://www.td2inc.com"
            }, 
            {
                "description": "Non-profit organization for pancreatic cancer research", 
                "url": "http://www.seenamagowitzfoundation.org"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "joschaffer@shc.org", 
                    "last_name": "Joyce Schaffer, MSN RN AOCNS", 
                    "phone": "480-323-1339"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85260"
                    }, 
                    "name": "Scottsdale Health Care"
                }, 
                "investigator": [
                    {
                        "last_name": "Gayle S Jameson, MSN ACNP-BC", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ramesh K Ramanathan, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel D Von Hoff, MD FACP", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Katy B Schroeder, RN BSN OCN", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "warrieac@cinj.rutgers.edu", 
                    "last_name": "Anjali Krishnan, RN", 
                    "phone": "732-235-8996"
                }, 
                "contact_backup": {
                    "email": "zelinska@cinj.rutgers.edu", 
                    "last_name": "Tatianna Zelinskaya", 
                    "phone": "732-235-9837"
                }, 
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08901"
                    }, 
                    "name": "Rutgers - Cancer Institute of New Jersey (CINJ)"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Popllin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nurses@vitahemonc.org", 
                    "last_name": "Colleen Saitta, NP", 
                    "phone": "610-866-0113"
                }, 
                "contact_backup": {
                    "email": "nurses@vitahemonc.org", 
                    "last_name": "Gulyun Zhou, NP", 
                    "phone": "610-866-0113"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethlehem", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18015"
                    }, 
                    "name": "Vita Medical Associates, PC"
                }, 
                "investigator": {
                    "last_name": "Anna A Niewiarowska, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)", 
        "overall_contact": {
            "email": "astoll@td2inc.com", 
            "last_name": "Amy Stoll-D'Astice, MS, CCRP", 
            "phone": "(602) 358-8319"
        }, 
        "overall_official": {
            "affiliation": "Scottsdale Health Care", 
            "last_name": "Gayle S Jameson, MSN ACNP-BC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objectives of this study is to pursue treatment of 25 individual patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDA) to evaluate:\nComplete response rate as defined by computed tomography (CT) scan using RECIST 1.1 criteria and CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) down to normal limits (from at least > 2x ULN).  We expect to accomplish this in > or = to 5% of patients.  When a complete response (CR) is documented, a confirmatory PET scan will be obtained.\nIf 1 or more of 10 patients demonstrate a complete response (CR), study will continue to enroll to a total of 25 patients.\nIf intolerable adverse events or no clinical benefit are noted in the first 6 patients, study will discontinue enrollment.", 
            "measure": "Complete Response Rate", 
            "safety_issue": "No", 
            "time_frame": "1 yr."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893801"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Pancreatic Cancer Research Team", 
            "investigator_full_name": "Gayle Jameson", 
            "investigator_title": "Lead Principal Investigator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate disease control rate (CR, PR and SD at 9 weeks) in patients with metastatic PDA.", 
                "measure": "Evaluate disease control rate", 
                "safety_issue": "No", 
                "time_frame": "9 weeks"
            }, 
            {
                "description": "Evaluate the treatment-related toxicities in this patient population.", 
                "measure": "Evaluate treatment-related toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "Over the course of the study"
            }, 
            {
                "description": "Evaluate the change in CA 19-9 (or CA 125, or CEA if not expressers of CA 19-9) in this patient population.", 
                "measure": "Evaluate the change in CA 19-9 or other biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Over the course of the study"
            }
        ], 
        "source": "Pancreatic Cancer Research Team", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Translational Genomics Research Institute, Phoenix, Arizona.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Translational Drug Development (TD2)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Virgina G. Piper Cancer Center - Clinical Trials", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Gayle Jameson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}